Longitudinal analysis of tumour‐derived cell‐free DNA levels tracks tumour responses and reveals heterogeneous resistance mechanisms: The majority depend on the EGFR pathway while a small subset developed alterative drivers that could be identified by tracking multiple mutations in plasma DNA. Here, EGFR is linked to neoplasm.